ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Summary

RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of prostate cancer. It is not yet known which dose of ZD 1839 is more effective in treating prostate cancer that has not responded to hormone therapy. PURPOSE: Randomized phase II trial to compare different doses of ZD 1839 in treating patients who have prostate cancer that has not responded to hormone therapy.

Timeline

Start

2001-04-24

Primary completion

2003-06-05

Completion

2008-09-22

Outcome

Missed primary endpoint

paper Gefitinib did not result in any responses in PSA or objective measurable disease at either dose level. PMID 15659491 ↗

Publications

• Results Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 2005 Jan 20;23(3):455-60. doi: 10.1200/JCO.2005.02.129.

Drugs

Indications